Sputnik V vaccine trials begin in India

Sputnik V vaccine trials begin in India
  • Clock-gray 18:58
  • calendar-gray 01 December 2020

The Russian Direct Investment Fund (RDIF) announced on Tuesday the second and third stages of clinical trials of the Sputnik V, a vaccine against coronavirus developed by Gamaleya Research Institute of Epidemiology and Microbiology, had begun in India, at Dr. Reddy's Laboratories Ltd, APA reports citing Teletrader.

"In India, after we obtain the necessary approval from the Central Laboratory for Medicines, the second and the third phases of the clinical trials [...] will begin. This will be a randomized controlled trial that will include safety and immunogenicity studies," the RDIF's statement read.

Back in November, the agency stated Indian pharmaceutical company Hetero asked for permission to produce its own doses of the Sputnik V, which previously proved to be "over 95% effective" against the virus.


Other news